>>500
ç¶ã
æœåšçãªã°ã¢ãã³åééïŒG-quadruplexïŒé åãååšããå¯èœæ§ãããããããããæ€èšŒããã«ã¯ãããé«åºŠãªã³ã³ãã¥ãŒã¿ãŒããã°ã©ã ãå¿ èŠã ã
ããã«ãã¯ã¯ãã³ RNA ã®ç¿»èš³ã«ãã£ãŠäœæãããã¹ãã€ã¯ã¿ã³ãã¯è³ªã¯ãäºéå«æé µçŽ ã§ããã¢ã³ãžãªãã³ã·ã³å€æé µçŽ 2ïŒACE2ïŒã«çµåããããã®çžäºäœçšã¯ã现èå äºéãå¢å ãããå¯èœæ§ããããäºéã€ãªã³ã¯ãTDP-43 ããã®ç çãªããªãªã³æ§æã«å€æããããšã瀺ãããŠããã
TDP-43 ãš FUS ãç çåŠçããªãªã³ç¢ºèªã«æãããããšãALSãåé èå€æ§ãã¢ã«ããã€ããŒç ããã®ä»ã®ç¥çµå€æ§çŸæ£ãåŒãèµ·ããããšãç¥ãããŠããã
åå°ããæèŠããã³è¿œå ã®æœåšçãªã¹ã¯ãããèè ã¯ãSARS-CoV-2 ã«å¯Ÿãã RNA ããŒã¹ã®ã¯ã¯ãã³ã®èŠå¶åœå±ã®æ¿èªã¯ææå°æ©ã§ããããããã®ã¯ã¯ãã³ã¯ããããã£ãããããã¯ããã«å€ãã®å®³ãåŒãèµ·ããå¯èœæ§ããããšç¢ºä¿¡ããŠããã
ç¶ã
æœåšçãªã°ã¢ãã³åééïŒG-quadruplexïŒé åãååšããå¯èœæ§ãããããããããæ€èšŒããã«ã¯ãããé«åºŠãªã³ã³ãã¥ãŒã¿ãŒããã°ã©ã ãå¿ èŠã ã
ããã«ãã¯ã¯ãã³ RNA ã®ç¿»èš³ã«ãã£ãŠäœæãããã¹ãã€ã¯ã¿ã³ãã¯è³ªã¯ãäºéå«æé µçŽ ã§ããã¢ã³ãžãªãã³ã·ã³å€æé µçŽ 2ïŒACE2ïŒã«çµåããããã®çžäºäœçšã¯ã现èå äºéãå¢å ãããå¯èœæ§ããããäºéã€ãªã³ã¯ãTDP-43 ããã®ç çãªããªãªã³æ§æã«å€æããããšã瀺ãããŠããã
TDP-43 ãš FUS ãç çåŠçããªãªã³ç¢ºèªã«æãããããšãALSãåé èå€æ§ãã¢ã«ããã€ããŒç ããã®ä»ã®ç¥çµå€æ§çŸæ£ãåŒãèµ·ããããšãç¥ãããŠããã
åå°ããæèŠããã³è¿œå ã®æœåšçãªã¹ã¯ãããèè ã¯ãSARS-CoV-2 ã«å¯Ÿãã RNA ããŒã¹ã®ã¯ã¯ãã³ã®èŠå¶åœå±ã®æ¿èªã¯ææå°æ©ã§ããããããã®ã¯ã¯ãã³ã¯ããããã£ãããããã¯ããã«å€ãã®å®³ãåŒãèµ·ããå¯èœæ§ããããšç¢ºä¿¡ããŠããã